159 related articles for article (PubMed ID: 24336958)
21. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic targets in melanoma: map kinase pathway.
Haluska FG; Ibrahim N
Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
[TBL] [Abstract][Full Text] [Related]
23. The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines.
Xie L; Meyskens FL
Melanoma Res; 2013 Apr; 23(2):102-13. PubMed ID: 23344158
[TBL] [Abstract][Full Text] [Related]
24. NRAS mutation status is an independent prognostic factor in metastatic melanoma.
Jakob JA; Bassett RL; Ng CS; Curry JL; Joseph RW; Alvarado GC; Rohlfs ML; Richard J; Gershenwald JE; Kim KB; Lazar AJ; Hwu P; Davies MA
Cancer; 2012 Aug; 118(16):4014-23. PubMed ID: 22180178
[TBL] [Abstract][Full Text] [Related]
25. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
Krisp C; Parker R; Pascovici D; Hayward NK; Wilmott JS; Thompson JF; Mann GJ; Long GV; Scolyer RA; Molloy MP
Br J Cancer; 2018 Sep; 119(6):713-723. PubMed ID: 30116025
[TBL] [Abstract][Full Text] [Related]
26. Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Kanazawa K; Kishimoto K; Nomura M; Kurosawa K; Kato H; Inoue Y; Miura K; Fukui K; Yamashita Y; Sato I; Tsuji H; Watanabe T; Tanaka T; Yasuda J; Tanuma N; Shima H
Cancer Sci; 2021 Jun; 112(6):2233-2244. PubMed ID: 33743547
[TBL] [Abstract][Full Text] [Related]
27. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
[TBL] [Abstract][Full Text] [Related]
28. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
29. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
30. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.
Mesbah Ardakani N; Leslie C; Grieu-Iacopetta F; Lam WS; Budgeon C; Millward M; Amanuel B
Pigment Cell Melanoma Res; 2017 Mar; 30(2):233-242. PubMed ID: 28002643
[TBL] [Abstract][Full Text] [Related]
31. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
32. The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization.
Deichmann M; Polychronidis M; Wacker J; Thome M; Näher H
Melanoma Res; 2001 Dec; 11(6):577-85. PubMed ID: 11725204
[TBL] [Abstract][Full Text] [Related]
33. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
34. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
35. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase CK2 phosphorylation of SAPS3 subunit increases PP6 phosphatase activity with Aurora A kinase.
Heo J; Larner JM; Brautigan DL
Biochem J; 2020 Jan; 477(2):431-444. PubMed ID: 31904830
[TBL] [Abstract][Full Text] [Related]
38. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
39. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
40. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Rubinstein JC; Sznol M; Pavlick AC; Ariyan S; Cheng E; Bacchiocchi A; Kluger HM; Narayan D; Halaban R
J Transl Med; 2010 Jul; 8():67. PubMed ID: 20630094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
